找回密碼
 To register

QQ登錄

只需一步，快速開始

掃一掃，訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Biosimilars for Cancer Treatment; A Promising Approach Shvetank Bhatt,Harish Dureja,Kamal Dua Book 2024 The Editor(s) (if applicable) and T

[復(fù)制鏈接]
查看: 18211|回復(fù): 54
樓主
發(fā)表于 2025-3-21 16:11:48 | 只看該作者 |倒序瀏覽 |閱讀模式
期刊全稱Biosimilars for Cancer Treatment
期刊簡稱A Promising Approach
影響因子2023Shvetank Bhatt,Harish Dureja,Kamal Dua
視頻videohttp://file.papertrans.cn/193/192718/192718.mp4
發(fā)行地址Covers the recent clinical trials of biosimilars for cancer treatment.Provides information about the analysis of regulatory complexities in cancer care.Explores the role of biosimilars in improving th
圖書封面Titlebook: Biosimilars for Cancer Treatment; A Promising Approach Shvetank Bhatt,Harish Dureja,Kamal Dua Book 2024 The Editor(s) (if applicable) and T
影響因子.The book delves into the role of biosimilars in the field of cancer treatment. It also discusses the application of biosimilars in various cancer types, from colorectal and cervical to prostate, gastric, lung, pancreatic, breast, hepatocellular, ovarian, and blood cancers...It contains chapters that focus on the clinical trials of biosimilars, providing insights into the latest research and developments...This book serves as a valuable resource for clinicians, researchers, and anyone seeking a comprehensive understanding of the intersection between biosimilars and cancer treatment..
Pindex Book 2024
The information of publication is updating

書目名稱Biosimilars for Cancer Treatment影響因子(影響力)




書目名稱Biosimilars for Cancer Treatment影響因子(影響力)學(xué)科排名




書目名稱Biosimilars for Cancer Treatment網(wǎng)絡(luò)公開度




書目名稱Biosimilars for Cancer Treatment網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Biosimilars for Cancer Treatment被引頻次




書目名稱Biosimilars for Cancer Treatment被引頻次學(xué)科排名




書目名稱Biosimilars for Cancer Treatment年度引用




書目名稱Biosimilars for Cancer Treatment年度引用學(xué)科排名




書目名稱Biosimilars for Cancer Treatment讀者反饋




書目名稱Biosimilars for Cancer Treatment讀者反饋學(xué)科排名




單選投票, 共有 0 人參與投票
 

0票 0%

Perfect with Aesthetics
 

0票 0%

Better Implies Difficulty
 

0票 0%

Good and Satisfactory
 

0票 0%

Adverse Performance
 

0票 0%

Disdainful Garbage
您所在的用戶組沒有投票權(quán)限
沙發(fā)
發(fā)表于 2025-3-21 21:48:20 | 只看該作者
板凳
發(fā)表于 2025-3-22 00:51:31 | 只看該作者
地板
發(fā)表于 2025-3-22 07:58:13 | 只看該作者
5#
發(fā)表于 2025-3-22 10:20:44 | 只看該作者
6#
發(fā)表于 2025-3-22 15:49:15 | 只看該作者
7#
發(fā)表于 2025-3-22 19:01:48 | 只看該作者
8#
發(fā)表于 2025-3-23 00:21:12 | 只看該作者
U. M. Lütolf,P. Huguenin,C. Glanzmann for use in both the disease itself and as supportive drugs for cancer patients. The reduction in the treatment cost using trastuzumab biosimilars is approximately 20–30% lower in comparison to the costs using the reference product. The supportive drugs include haematopoietic growth factors like ery
9#
發(fā)表于 2025-3-23 01:35:18 | 只看該作者
10#
發(fā)表于 2025-3-23 09:02:06 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-13 10:19
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
页游| 澄迈县| 环江| 兴城市| 苍南县| 呈贡县| 四平市| 本溪| 淮北市| 苏尼特右旗| 明光市| 桐柏县| 临西县| 万盛区| 新疆| 怀远县| 九龙县| 合作市| 客服| 房产| 台南市| 新沂市| 漠河县| 木兰县| 西乌珠穆沁旗| 舞钢市| 永修县| 南丰县| 五常市| 丰原市| 个旧市| 宁陵县| 房产| 如皋市| 靖远县| 平利县| 什邡市| 盱眙县| 弥渡县| 长丰县| 八宿县|